Published in Am J Clin Pathol on March 01, 2007
Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol (2011) 2.38
Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay. PLoS One (2016) 0.81
Comparing computer-generated and pathologist-generated tumour segmentations for immunohistochemical scoring of breast tissue microarrays. Br J Cancer (2015) 0.77
An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. Virchows Arch (2016) 0.77
Comparison of evaluations of hormone receptors in breast carcinoma by image-analysis using three automated immunohistochemical stainings. Exp Ther Med (2010) 0.76
Study assessing the quality of quantification of estrogen receptor protein expression by immunohistochemistry and gene expression in breast cancer. Patholog Res Int (2014) 0.76
Severe acute interstitial pneumonia and gefitinib. Lancet (2003) 3.94
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol (2008) 2.90
miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer. Cancer Res (2008) 2.80
Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. Eur Urol (2008) 2.80
Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer. Am J Surg (2008) 2.43
One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res (2007) 2.36
Transcatheter arterial embolization of acute arterial bleeding in the upper and lower gastrointestinal tract with N-butyl-2-cyanoacrylate. J Vasc Interv Radiol (2013) 2.21
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg (2009) 2.02
NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res (2008) 2.01
Sentinel node tumour burden quantified based on cytokeratin 19 mRNA copy number predicts non-sentinel node metastases in breast cancer: molecular whole-node analysis of all removed nodes. Eur J Cancer (2012) 2.01
New terminology for intrauterine endometrial samples: a group study by the Japanese Society of Clinical Cytology. Acta Cytol (2012) 1.99
HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res (2004) 1.74
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat (2005) 1.71
The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast (2007) 1.64
Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer (2015) 1.64
Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res (2004) 1.63
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res (2012) 1.56
Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol (2007) 1.56
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat (2011) 1.55
Magnetic resonance-guided focused ultrasound surgery of breast cancer: reliability and effectiveness. J Am Coll Surg (2006) 1.53
Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res (2009) 1.52
Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability. Hum Pathol (2002) 1.51
The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat Cell Biol (2009) 1.51
Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy. Cancer Res (2005) 1.51
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med (2013) 1.46
Bone mineral density in breast cancer patients with positive estrogen receptor tumor status. Maturitas (2007) 1.45
Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer (2004) 1.41
Clear cell hidradenoma of the breast: a case report with review of the literature. Breast Cancer (2007) 1.40
Aryl hydrocarbon receptor suppresses intestinal carcinogenesis in ApcMin/+ mice with natural ligands. Proc Natl Acad Sci U S A (2009) 1.40
Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab (2003) 1.38
In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer (2005) 1.37
Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer (2008) 1.37
Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci (2004) 1.31
Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer (2006) 1.28
Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res (2006) 1.26
Flare-up of dermatomyositis along with recurrence of breast cancer. Breast J (2007) 1.25
Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat (2006) 1.25
Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res (2003) 1.25
Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat (2007) 1.25
Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol (2009) 1.24
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci (2007) 1.24
The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer (2007) 1.23
Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. Histopathology (2011) 1.22
Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J (2005) 1.19
A case of carcinosarcoma of the breast. Breast Cancer (2005) 1.18
Autoimmune pancreatitis with hepatic inflammatory pseudotumor. Pancreas (2005) 1.18
Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab (2012) 1.17
Microdissection is essential for gene expression profiling of clinically resected cancer tissues. Am J Clin Pathol (2002) 1.17
Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer (2005) 1.17
Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol (2008) 1.16
Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res (2004) 1.16
Pulmonary mucinous cystadenocarcinoma: report of a case and review of the literature. Ann Thorac Surg (2003) 1.15
Reproductive history and breast cancer risk. Breast Cancer (2012) 1.14
Hepatoid adenocarcinoma of the gallbladder: Case report and review of the literature. Pathol Int (2004) 1.14
Two cases of ductal adenoma of the breast. Breast Cancer (2006) 1.14
Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood (2010) 1.13
Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer. Clin Cancer Res (2006) 1.13
Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrinol Metab (2002) 1.12
Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler Thromb Vasc Biol (2006) 1.11
Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci (2011) 1.11
Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci (2012) 1.10
Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia. Pathol Int (2002) 1.10
Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. Psychooncology (2011) 1.10
Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer (2005) 1.10
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer (2010) 1.09
Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int (2005) 1.09
Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer (2008) 1.09
Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol (2007) 1.09
Lactogens promote beta cell survival through JAK2/STAT5 activation and Bcl-XL upregulation. J Biol Chem (2007) 1.08
Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas. Pancreatology (2008) 1.08
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res (2007) 1.08
Expression of core 2 beta1,6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology (2005) 1.08
General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer (2005) 1.08
Interactions between prostaglandin E(2), liver receptor homologue-1, and aromatase in breast cancer. Cancer Res (2005) 1.07
Patients' supportive care needs and psychological distress in advanced breast cancer patients in Japan. Jpn J Clin Oncol (2010) 1.07
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol (2011) 1.07
Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer. Breast Cancer Res Treat (2011) 1.07
Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Breast Cancer Res Treat (2009) 1.07
Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol (2010) 1.06
Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer (2012) 1.06
Clinical and pathologic evaluation of implanted free dermal fat grafts after breast cancer surgery: a retrospective analysis. Surgery (2011) 1.06
Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett (2003) 1.05
Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res (2007) 1.05
Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem Biophys Res Commun (2006) 1.05
Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer (2006) 1.05
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol (2008) 1.05
Gastric schwannomas show an obviously increased fluorodeoxyglucose uptake in positron emission tomography: report of two cases. Surg Today (2011) 1.05
Two cases of breast cancer with cartilaginous and osseous metaplasia. Breast Cancer (2005) 1.04
Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer. Cancer Sci (2008) 1.04